Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
IMTX has dropped 22% in a month, yet one of its largest shareholders just went on the SEC register as an activist, making the gap between institutional conviction and market direction the defining tension this week.
The most newsworthy fact in the snapshot is Perceptive Advisors filing a Schedule 13D on IMTX on August 27, disclosing a 7.6% stake of 11.4 million shares. A 13D signals active intent, not passive ownership. That filing arrived within days of Perceptive making an open-market purchase of 863,060 shares at $8.69, a $7.5 million transaction filed with the SEC on August 26, executed outside any pre-planned 10b5-1 arrangement. That is discretionary conviction buying, and the activist flag elevates it further. As always with 13D/G disclosures, the stake is as-last-disclosed around the 5% threshold; Perceptive could have moved since without further filing.
The borrow market tells a story that doesn't match an impending squeeze. Short interest has fallen sharply, down 17% over the past week and 25% over the past month, now at just 3% of the free float. Availability is extremely loose at over 1,000%, meaning there are roughly ten shares available to borrow for every one already shorted. Cost to borrow collapsed to 0.097% on October 13, a fraction of where it was even a week earlier. Shorts are exiting, not pressing. The ORTEX short score has eased to 46.3 from 52 at the start of October, moving in the same direction. What's left is a small, retreating short position in a liquid borrow market. That removes squeeze risk but also removes any obvious technical catalyst from covering pressure.
Options positioning is almost entirely call-sided, a rare configuration for a stock falling this fast. The put/call ratio of 0.14 is far below its 20-day average of 0.56. A year ago that ratio reached 4.14. The complete reversal suggests the options market is now populated almost exclusively by call buyers, either speculative longs or investors hedging existing short positions by purchasing upside. It is not a defensive setup by any conventional measure, which makes it an unusual pairing with a stock down 9% on the week.
The Street is firmly bullish, though the gap between targets and reality is wide. Nine analysts carry Buy ratings. Stifel initiated coverage this week with a Buy and a $15 target. Jefferies assumed with a Buy at $18 in March. Chardan holds its $25 target. The consensus mean target of $17.26 against a close of $6.83 implies the Street sees roughly 150% upside, a gap that reflects pre-commercialisation uncertainty as much as conviction. The bull case rests on the T-cell redirecting pipeline, $505.8 million in cash through at least the second half of 2027, and potential global sales of €573.7 million by 2035. The bear case is straightforward: the pipeline may disappoint, competition in T-cell therapy is intensifying, and the company will almost certainly need additional capital before it reaches profitability.
Ownership concentration is heavy. T. Rowe Price holds 16.7% and added shares through June. RTW Investments holds 9.5%. Baker Bros. trimmed to 7% from nearly 10% in its most recent disclosure. Wellington cut its position from 7.1% to 4.4% and has now fallen below the 5% threshold. With the next earnings event scheduled for November 13, thirty days out, the watch points are any pipeline readout that shifts the clinical probability assessments the Street has priced in, and whether Perceptive's activist stance produces any visible change in company direction.
See the live data behind this article on ORTEX.
Open IMTX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
